Brief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
05/10/2026 22:43
BRIEF-Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504 Oct 5 (Reuters) - Equillium Inc EQ.O:
EQUILLIUM RECEIVES AUSTRALIAN REGULATORY CLEARANCE TO INITIATE FIRST-IN-HUMAN CLINICAL TRIAL OF EQ504
EQUILLIUM - EXPECTS TO BEGIN DOSING BY EARLY NOVEMBER 2026
EQUILLIUM - TOPLINE PHASE 1 DATA EXPECTED SIX MONTHS AFTER STUDY INITIATION
Source text: ID:nGNX89Hf7F
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations